You just read:

Sangamo Announces Interim Results Of Phase 1/2 CHAMPIONS Study Showing Preliminary Evidence Of In Vivo Genome Editing In Patients With MPS II Treated With SB-913

News provided by

Sangamo Therapeutics, Inc.

Feb 07, 2019, 11:00 ET